Attovia Therapeutics, Inc. (ATTO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,412 | 1,449 | - | - | 0 | 1 | 0 | 0 |
| Operating profit | $m | -67 | -42 | ||||||
| Net profit | $m | -47 | -90 | - | - | -40 | -61 | -39 | - |
| EPS reported | $ | -1.42 | -0.93 | ||||||
| Operating cashflow per share | $ | -1.38 | -0.77 | ||||||
| Capex per share | $ | 0.05 | 0.01 | ||||||
| FCF per share | $ | -1.43 | -0.77 | ||||||
| Free cash flow | $m | -62 | -35 | ||||||
| Net debt | $m | -150 | -111 | ||||||
| Book value equity | $m | 151 | 113 | ||||||
| Book value per share | $ | 3.50 | 2.47 | ||||||
| Number of shares | m | 43.03 | 45.65 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 6.25 | 8.36 | ||||||
| P/S LTM | x | 698.03 | 2,094.08 | ||||||
| P/FCF LTM | x | -15.32 | -26.70 | ||||||
| EV/EBITDA LTM | x | -13.67 | -21.99 | ||||||
| EV/Sales LTM | x | 672.15 | 2,379.81 | ||||||
| Earnings Yield LTM | % | -6.43% | -3.37% | ||||||
| FCF Yield | % | -6.53% | -3.75% | ||||||
| Quality | |||||||||
| ROE | % | -40.21% | -32.05% | ||||||
| ROIC | % | -42.83% | -35.46% | ||||||
| Operating margin | % | -49.75% | -92.80% | ||||||
| Gross margin | % | +40.44% | -8.44% | ||||||
| FCF/Sales | % | -4556.4% | -7842.9% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -11.69 | -8.16 | ||||||
| Net Debt/EBITDA | x | 0.53 | 0.69 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.20% | +0.19% | ||||||
| Net debt/Equity | x | -1.00 | -0.98 | ||||||
| Gross debt/equity | x | 0.03 | 0.04 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Attovia Therapeutics, Inc. (ATTO)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free